Spero Therapeutics Inc (SPRO)
1.175
-0.02
(-1.26%)
USD |
NASDAQ |
Nov 22, 16:00
1.175
0.00 (0.00%)
After-Hours: 17:52
Spero Therapeutics Net Income (Quarterly): -17.15M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -17.15M |
| June 30, 2024 | -17.86M |
| March 31, 2024 | -12.67M |
| December 31, 2023 | 51.19M |
| September 30, 2023 | -3.205M |
| June 30, 2023 | -11.91M |
| March 31, 2023 | -13.27M |
| December 31, 2022 | 26.77M |
| September 30, 2022 | -11.68M |
| June 30, 2022 | -28.68M |
| March 31, 2022 | -32.83M |
| December 31, 2021 | -29.24M |
| September 30, 2021 | -22.52M |
| June 30, 2021 | -18.57M |
| March 31, 2021 | -19.42M |
| December 31, 2020 | -18.58M |
| September 30, 2020 | -18.94M |
| Date | Value |
|---|---|
| June 30, 2020 | -17.50M |
| March 31, 2020 | -23.26M |
| December 31, 2019 | -24.99M |
| September 30, 2019 | -17.72M |
| June 30, 2019 | -13.15M |
| March 31, 2019 | -5.072M |
| December 31, 2018 | -10.60M |
| September 30, 2018 | -10.46M |
| June 30, 2018 | -9.956M |
| March 31, 2018 | -10.64M |
| December 31, 2017 | -13.86M |
| September 30, 2017 | -9.836M |
| June 30, 2017 | -9.169M |
| March 31, 2017 | -5.876M |
| December 31, 2016 | -7.211M |
| September 30, 2016 | -6.316M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-32.83M
Minimum
Mar 2022
51.19M
Maximum
Dec 2023
-13.22M
Average
-18.22M
Median
Net Income (Quarterly) Benchmarks
| Arbutus Biopharma Corp | -19.72M |
| Equillium Inc | -0.007M |
| NovaBay Pharmaceuticals Inc | -1.212M |
| Palatin Technologies Inc | -7.824M |
| iBio Inc | -3.989M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 7.819M |
| Total Expenses (Quarterly) | 26.41M |
| EPS Diluted (Quarterly) | -0.32 |
| Enterprise Value | -11.41M |
| Profit Margin (Quarterly) | -219.3% |
| Earnings Yield | 6.81% |
| Normalized Earnings Yield | 6.809 |